Melatonin
Important Information for the Patient.
This medication should always be taken exactly as described in this patient leaflet or according to the doctor's or pharmacist's instructions.
Melabiorytm, 5 mg, tablets contain the active substance melatonin. This hormone occurs naturally in the human body. It is produced by the pineal gland, located in the central nervous system. Melatonin plays an important role in regulating the biological daily rhythm. It regulates sleep and wakefulness during the day.
Melabiorytm is indicated as an auxiliary agent in sleep disorders associated with time zone changes or shift work, and to facilitate the regulation of the daily sleep-wake rhythm in blind patients.
Before starting to take Melabiorytm, the doctor or pharmacist should be consulted:
This medication should not be taken by children and adolescents from 0 to 18 years of age, as it has not been tested in this group of patients and its effects are unknown.
The doctor or pharmacist should be informed about all medications currently being taken by the patient, as well as any medications planned to be taken.
Fluvoxamine (an antidepressant) and other medications that undergo liver metabolism, such as citalopram (an antidepressant), omeprazole, lansoprazole (medications used for stomach ulcers and gastroesophageal reflux disease) increase the blood concentration of melatonin taken at the same time.
Other medications that may affect melatonin:
Alcohol should not be consumed while taking Melabiorytm, as it reduces the effectiveness of the medication.
If the patient is pregnant or breastfeeding, suspects that she may be pregnant, or plans to have a child, she should consult a doctor or pharmacist before taking this medication.
The medication is contraindicated during pregnancy and breastfeeding.
After taking the medication, the patient should not drive vehicles or operate machinery, as drowsiness may occur, leading to decreased concentration.
This medication should always be taken exactly as described in this patient leaflet or according to the doctor's or pharmacist's instructions. In case of doubts, the doctor or pharmacist should be consulted.
The tablet should be swallowed with water.
Dosage
Adults:
In sleep disorders associated with time zone changes:
2 mg to 3 mg of melatonin once a day, after dark, starting from the first day of travel. The treatment should be continued for 2 to 3 consecutive days after the end of the trip.
In sleep-wake rhythm disorders associated with shift work:
1 mg to 5 mg per day, 1 hour before bedtime.
In sleep-wake rhythm disorders in blind patients,
0.5 mg to 5 mg should be taken once a day, around 9-10 pm. This dosage also applies to long-term use of the medication.
The effect of the medication in the treatment of long-term sleep-wake rhythm disorders may be observed sometimes only after 2 weeks of taking the medication.
The established medical use of melatonin includes doses from 0.5 mg; the smallest effective dose of melatonin should be used.
Melabiorytm should only be used when the effectiveness of other, lower doses of melatonin available on the market has not been demonstrated.
In case of accidental ingestion of too high a dose, the doctor or pharmacist should be contacted as soon as possible.
Taking a higher dose than recommended may, in individual cases, cause drowsiness, disorientation, or psychosis.
A double dose should not be taken to make up for a missed dose.
No harmful effects of stopping or ending treatment early have been reported. No withdrawal symptoms have been observed after stopping Melabiorytm treatment.
In case of any further doubts about the use of this medication, the doctor or pharmacist should be consulted.
Like all medications, Melabiorytm can cause side effects, although not everybody gets them.
Uncommon(may occur in less than 1 in 100 people):
Rare(may occur in less than 1 in 1000 people):
Frequency not known(cannot be estimated from the available data):
If any side effects occur, including those not listed in this leaflet, the doctor or pharmacist, or nurse should be informed. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw,
tel.: 22 49-21-301,
fax: 22 49-21-309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help gather more information on the safety of the medication.
The medication should be stored out of sight and reach of children.
Store in a temperature below 25°C, in the original packaging to protect from light.
Do not use this medication after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medications should not be disposed of via wastewater or household waste containers. The pharmacist should be asked how to dispose of unused medications. This will help protect the environment.
The medication is round, white, biconvex, uncoated tablets.
Aluminum/PVC/PVDC blisters in a cardboard box.
Pack sizes: 30, 60, or 90 tablets.
Aflofarm Farmacja Polska Sp. z o.o.
ul. Partyzancka 133/151
95-200 Pabianice
Tel. (42) 22-53-100
Aflofarm Farmacja Polska Sp. z o.o.
ul. Szkolna 31
95-054 Ksawerów
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.